Depatuxizumab mafodotin in glioblastoma: A systematic review of efficacy, safety, pharmacokinetics and biomarker stratification
{{output}}
BackgroundGlioblastoma (GBM) is an aggressive primary brain tumor with a dismal prognosis. Alterations in the Epidermal Growth Factor Receptor (EGFR) in about half of the cases, represent a key therapeutic target. Depatuxizumab mafodotin (Depatux-M) is an anti... ...
